100 related articles for article (PubMed ID: 8184567)
21. [Monitoring markers of bone turnover in multiple myeloma].
Spicka I; Spacek P; Hulejová H; Procházka B; Cieslar P; Chrz M; Válková V; Klener P
Vnitr Lek; 1999 Aug; 45(8):463-7. PubMed ID: 11045145
[TBL] [Abstract][Full Text] [Related]
22. [The comparison of serum levels of selected biomarkers in monoclonal gammopathy of undetermined significance and multiple myeloma].
Scudla V; Budíková M; Pika T; Bacovský J; Minarík J; Heinzová V; Langová K
Cas Lek Cesk; 2009; 148(7):315-22. PubMed ID: 19642297
[TBL] [Abstract][Full Text] [Related]
23. Circulating angiogenic cytokines in multiple myeloma and related disorders.
Urba ska-Rys H; Wierzbowska A; Robak T
Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
[TBL] [Abstract][Full Text] [Related]
24. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
[TBL] [Abstract][Full Text] [Related]
25. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
Perosa F; Minoia C; Favoino E; Prete M; Dammacco F
Blood Cells Mol Dis; 2009; 42(1):71-6. PubMed ID: 18996035
[TBL] [Abstract][Full Text] [Related]
26. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
Tao ZF; Fu WJ; Chen YB; Yuan ZG; Wang DX; Hou J
Ai Zheng; 2006 Apr; 25(4):461-4. PubMed ID: 16613681
[TBL] [Abstract][Full Text] [Related]
27. A non-radiometric method for measuring serum thymidine kinase activity in malignant lymphoma in dogs.
von Euler HP; Ohrvik AB; Eriksson SK
Res Vet Sci; 2006 Feb; 80(1):17-24. PubMed ID: 16140350
[TBL] [Abstract][Full Text] [Related]
28. [Serum beta 2-microglobulin in multiple myeloma. II. Its significance in monitoring the disease].
Scudla V; Budíková M; Fischerová E; Raska I; Vavrdová V
Vnitr Lek; 1991 May; 37(5):479-87. PubMed ID: 1842146
[TBL] [Abstract][Full Text] [Related]
29. Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression.
Matthews C; Catherwood MA; Morris TC; Kettle PJ; Drake MB; Gilmore WS; Alexander HD
Eur J Haematol; 2006 Oct; 77(4):309-17. PubMed ID: 16856923
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of thymidine kinase activity in bladder carcinoma.
Mizutani Y; Wada H; Yoshida O; Fukushima M; Kamoi K; Miki T
Cancer; 2002 Nov; 95(10):2120-5. PubMed ID: 12412165
[TBL] [Abstract][Full Text] [Related]
31. High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
Urbańska-Ryś H; Robak T
Mediators Inflamm; 2003 Aug; 12(4):229-35. PubMed ID: 14514474
[TBL] [Abstract][Full Text] [Related]
32. [Contribution to the evaluation of the relationship between angiogenic cytokines, selected biological parameters and prognostic factors in multiple myeloma].
Scudla V; Pika T; Budíková M; Ordeltová M; Minarík J; Zemanová M; Bacovský J; Srovnalík K;
Cas Lek Cesk; 2006; 145(12):929-35. PubMed ID: 17323615
[TBL] [Abstract][Full Text] [Related]
33. Clinical significance of telomerase activity in multiple myeloma.
Shiratsuchi M; Muta K; Abe Y; Motomura S; Taguchi F; Takatsuki H; Uike N; Umemura T; Nawata H; Nishimura J
Cancer; 2002 Apr; 94(8):2232-8. PubMed ID: 12001122
[TBL] [Abstract][Full Text] [Related]
34. [Prognostic factors and markers of activity in multiple myeloma (results of the Cooperative Group for Diagnosis and Treatment of Multiple Myeloma)].
Spicka I; Cieslar P; Procházka B; Jirsa M; Chrz M; Gregora E; Klener P
Cas Lek Cesk; 2000 Apr; 139(7):208-12. PubMed ID: 10916207
[TBL] [Abstract][Full Text] [Related]
35. An in-house assay for serum deoxythymidine kinase.
Seah LH; Ton SH; Cheong SK; Hamidah NH
Malays J Pathol; 1991 Dec; 13(2):109-13. PubMed ID: 1823092
[TBL] [Abstract][Full Text] [Related]
36. Analysis of criteria in staging in multiple myeloma.
Pennec Y; Mottier D; Youinou P; Asselain B; Miossec P; Le Goff P; Le Prise PY; Le Menn G
Haematologia (Budap); 1982; 15(2):221-6. PubMed ID: 7160667
[TBL] [Abstract][Full Text] [Related]
37. Serum levels of interleukin-15 and interleukin-10 and their correlation with proliferating cell nuclear antigen in multiple myeloma.
Pappa C; Miyakis S; Tsirakis G; Sfiridaki A; Alegakis A; Kafousi M; Stathopoulos EN; Alexandrakis MG
Cytokine; 2007 Feb; 37(2):171-5. PubMed ID: 17446083
[TBL] [Abstract][Full Text] [Related]
38. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.
Alexandrakis MG; Sfiridaki A; Miyakis S; Pappa C; Kandidaki E; Alegakis A; Margioris AN
Clin Chim Acta; 2007 Apr; 379(1-2):31-5. PubMed ID: 17234170
[TBL] [Abstract][Full Text] [Related]
39. Changes of serum thymidine kinase in children with acute leukemia.
Votava T; Topolcan O; Holubec L; Cerna Z; Sasek L; Finek J; Kormunda S
Anticancer Res; 2007; 27(4A):1925-8. PubMed ID: 17649797
[TBL] [Abstract][Full Text] [Related]
40. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.
Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P
Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
